Conditions: Neoplasm Metastasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.

Detailed description:

Arms:
arm 1: Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.

Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Interventions: intervention 1: LY2940680
Intervention descriptions: intervention 1: Administered orally

Protocol document: